Phase III data on Vivlodex (meloxicam) shows patients on this therapy use less medication for pain: osteoarthritis- Iroko Pharma

Iroko Pharmaceuticals announced that new data from a Phase III study in patients with osteoarthritis (OA) pain demonstrated patients treated with Vivlodex (meloxicam) capsules consistently used less rescue pain medication, regardless of time of day, compared to patients receiving placebo. Patients receiving Vivlodex 5 mg and 10 mg used significantly less total rescue medication, took fewer daily doses of rescue medication and for fewer days compared with patients receiving placebo. The greatest benefits were seen in patients taking Vivlodex 10 mg.

Regardless of the time of day, patients receiving Vivlodex 10 mg per day took about half as many rescue pain medication doses as patients receiving placebo. Patients in the 10 mg (48.4) and 5 mg (52.4) groups received significantly fewer doses of rescue medication over 12-weeks than those in the placebo group (73.2). In addition, the mean daily rescue medication dosage was significantly lower in the 10 mg group (313.6) and 5 mg (326.2) group compared to placebo (464.1). The mean number of days with a rescue event was significantly less in the 10 mg group (23.5) and 5 mg (25.3) group compared to placebo (33.9). Finally, a dose-related trend was observed in the average number of rescue events per patient over 12-weeks by time of day. The results were presented at the 35th Annual Scientific Meeting of the American Pain Society.